On February 9, 2026, the World Health Expo Dubai (WHX Dubai) opened with great fanfare at the Dubai Exhibition Centre in the United Arab Emirates. Global policymakers, clinical experts, and investors gathered at the event. As one of the Middle East’s most influential healthcare exhibitions, this year’s show reached a record-breaking scale—drawing 4,300 exhibitors and 235,000 industry professionals from more than 180 countries. Thirty-two national pavilions were on display, with leading medical powers such as China, Germany, and the United States participating, while new entrants like Slovakia and Thailand joined, further elevating the event’s international reach and industry influence.

1. An innovative product portfolio that demonstrates technological depth. 
At the exhibition, Nanjing Shuangwei Biotechnology showcased its range of single-use leukoreduction transfusion devices, plasma virus‑inactivation transfusion systems, PRP product lines, and wound care solutions. Among these, the single-use platelet‑rich plasma (PRP) preparation kit drew particular attention with its groundbreaking “single centrifugation, one‑stop closed system, one‑button preparation” technology, earning widespread acclaim from international visitors. Meanwhile, complementary equipment—including catheter blood draining forceps, heat‑sealing machines, and intelligent blood separators—was also on display, fully demonstrating the company’s integrated capabilities across products, systems, hardware, and services. This not only underscores the company’s deep technical expertise in the medical device sector but also highlights its professional value in enhancing clinical efficiency and patient safety.

2. Strong expertise wins recognition, bringing fruitful collaboration opportunities 
With more than two decades of expertise in the medical device sector, Nanjing Shuangwei Biotechnology has amassed over 100 proprietary technologies, and its products are now exported to more than 50 countries. During the trade show, the company’s international export team engaged in in-depth discussions with distributors from the Middle East, Europe, Africa, Southeast Asia, and other regions. Core innovations such as leukocyte depletion technology and viral inactivation systems have earned unanimous acclaim from international partners.

3. Growing platform strengths empower global healthcare partners. 
Nanjing Shuangwei Biotechnology, with a core focus on safe blood transfusion and wound care, has simultaneously established three robust support platforms—sterilization services, medical device distribution, and R&D and manufacturing of advanced materials—creating a diversified, synergistic business model that provides a solid foundation for international partnerships. At this exhibition, the company showcased its end-to-end capabilities—from R&D and manufacturing to sterilization services—further elevating its global brand influence to a new level.

4. Looking ahead, we will jointly open a new chapter for the industry. 
This trip to Dubai marks a pivotal step in Nanjing Shuangwei Biotechnology’s global expansion strategy. Through in-depth dialogues with the global industry players, the company has gained clearer insights into global market demands and future trends. Moving forward, Shuangwei Biotechnology will remain committed to innovation, leveraging its platform and state-of-the-art industrial park to deliver safer medical solutions to customers worldwide. The company will continue to showcase its offerings at international trade shows, deepen collaboration with global partners, and jointly elevate blood transfusion safety and wound care technologies to new heights, contributing further expertise to the cause of global healthcare.